Dr. Bethany M. Mikles

Hematology | Oncology
Naval Medical Center
620 John Paul Jones Cir, 
Portsmouth, VA 
Clinical Trials:Currently Recruiting for 3 Trials
Naval Medical Center
620 John Paul Jones Cir, 
Portsmouth, VA 

Overview

Bethany Mikles is a Hematologist and an Oncologist practicing medicine in Portsmouth, Virginia.

Her clinical expertise encompasses Ependymoma, Ewing Sarcoma, Pheochromocytoma, Gliomatosis Cerebri, and Bone Marrow Aspiration.

She is actively involved in clinical research, co-authoring 2 peer reviewed articles and participating in 28 clinical trials.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in VA

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Naval Medical Center
620 John Paul Jones Cir, Portsmouth, VA 23708

Additional Areas of Focus

Dr. Mikles has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

28 Clinical Trials

The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Other
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Procedure, Biological, Drug, Other
Study Drugs: Bleomycin, Bleomycin Sulfate, Carboplatin, Cisplatin, Etoposide, Etoposide Phosphate
Study Phase: Phase 3
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Calaspargase, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Inotuzumab, Leucovorin, 6-Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Thioguanine, Vincristine
Study Phase: Phase 3
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Radiation, Drug, Biological, Other
Study Drugs: Cyclophosphamide, Dactinomycin, Irinotecan hydrochloride, Temsirolimus, Vincristine sulfate, Vinorelbine
Study Phase: Phase 3
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Other, Procedure
Study Drugs: Carboplatin, Cisplatin, Doxorubicin, Etoposide, Fluorouracil, Gemcitabine, Irinotecan, Oxaliplatin, Sorafenib, Vincristine Sulfate
Study Phase: Phase 3
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Drug, Procedure, Other, Biological
Study Drugs: Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Hydrocortisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations
Enrollment Status: Active_not_recruiting
Publish Date: August 03, 2026
Intervention Type: Procedure, Drug
Study Drug: Selpercatinib
Study Phase: Phase 2
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2026
Intervention Type: Drug, Biological, Radiation
Study Drugs: Erwinia Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Prednisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Enrollment Status: Active_not_recruiting
Publish Date: July 29, 2026
Intervention Type: Drug, Radiation
Study Drugs: Bortezomib, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin, Doxorubicin, Etoposide, Hydrocortisone Sodium Succinate, Ifosfamide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
View 7 Less Clinical Trials

2 Total Publications

Pediatric hematology providers on referral for transplant evaluation for sickle cell disease: a regional perspective.
Pediatric hematology providers on referral for transplant evaluation for sickle cell disease: a regional perspective.
Journal: Journal of pediatric hematology/oncology
Published: March 18, 2014
Similar Doctors
Expertise in
29
conditions
Dr. Lloyd A. Shabazz
Hematology | Oncology
Expertise in
29
conditions
Dr. Lloyd A. Shabazz
Hematology | Oncology
Referral may be required

Bon Secours Maryview Outpatient Infusion

355 Crawford St Ste 300, 
Portsmouth, VA 
 (1.4 miles away)
757-396-6333
Languages Spoken:
English
See accepted insurances

Lloyd Shabazz is a Hematologist and an Oncologist practicing medicine in Portsmouth, Virginia. Dr. Shabazz is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Myelodysplastic Syndrome (MDS), Paget Disease of the Breast, Inflammatory Breast Cancer, and Sickle Cell Disease.

Expertise in
40
conditions
Expertise in
40
conditions
Referral may be required

Mayo Clinic-Rochester

5716 Cleveland St Ste 200, 
Virginia Beach, VA 
 (8.5 miles away)
507-284-2511
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mrinal Patnaik is a Hematologist practicing medicine in Virginia Beach, Virginia. Dr. Patnaik is highly rated in 40 conditions, according to our data. His clinical expertise encompasses Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Patnaik is currently accepting new patients.

Expertise in
21
conditions
Expertise in
21
conditions
Referral may be required

Mayo Clinic-Rochester

5716 Cleveland St Ste 200, 
Virginia Beach, VA 
 (8.5 miles away)
507-284-2511
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Animesh Pardanani is a Hematologist practicing medicine in Virginia Beach, Virginia. Dr. Pardanani is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Myelofibrosis, Systemic Mastocytosis, Essential Thrombocythemia, Splenectomy, and Bone Marrow Aspiration. Dr. Pardanani is currently accepting new patients.

Frequently Asked Questions about Dr. Bethany M. Mikles

How do I make an appointment with Dr. Bethany M. Mikles?

You can book an appointment with Dr. Bethany M. Mikles by calling their office at 757-953-4529. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Bethany M. Mikles a top-rated expert for Ependymoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Bethany M. Mikles is classified as an Experienced expert for Ependymoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Bethany M. Mikles specialize in?

While Dr. Bethany M. Mikles is a Hematology, they have specific expertise in Ependymoma, Ewing Sarcoma, and Pheochromocytoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Bethany M. Mikles participate in research or clinical trials?

Yes. Dr. Bethany M. Mikles has published 2 articles and abstracts on conditions like Ependymoma. You can view a list of Dr. Bethany M. Mikles's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mikles's expertise for a condition
ConditionClose
        View All 25 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile